Table 7 Univariate analysis of factors affecting CI-AKI

Demographics and co-morbidities

Age (years) mean ± SD

61.54 ± 6.4

59.65 ± 7.5

-5.3

1.5

t= -1.095

p = 0.299

Gender, number (%)

Male

Female

12 (54.5%)

10 (45.5%)

52 (53.1%)

46 (46.9%)

0.3

0.9

X² = 0.2

p = 0.9

BMI (Kg/m²), mean ± SD

30.83 ± 4.7

31.4 ± 3.3

-1.08

2.3

t = 0.71

p = 0.51

DM

14 (63.6%)

33 (33.7%)

0.23

1.067

X² = 6.7

p = 0.009

HTN

17 (77.3%)

56 (57.1%)

0.4

1.2

X² = 3.05

p = 0.08

Dyslipidemia

16 (72.7%)

60 (61.2%)

0.46

1.18

X² = 1.02

p = 0.3

Stroke

2 (9.1%)

11 (11.2%)

0.056

0.3

 F = 0.08

p = 0.7

Malignancy

0 (0%)

3 (3.1%)

0.006

0.17

X² = 0.02

p = 0.4

Baseline laboratory investigations

Urea

54.59 ± 9.1

47.85 ± 12.27

-12.2

-1.2

t= -2.4

p = 0.017

Creatinine

1.8 ± 0.26

1.5 ± 0.19

-0.39

-0.2

t= -6.22

p = 0.0001

Uric acid

5.7 ± 1.15

5.56 ± 1.3

-0.74

0.455

t= -0.466

p = 0.471

Cholesterol

194.22 ± 16.93

194.59 ± 17.66

-7.86

8.46

t = 0.073

p = 0.930

Triglycerides

141.22 ± 25.04

143.39 ± 15.6

-6.07

10.42

t = 0.53

p = 0.604

HDL

59.22 ± 9.4

59.69 ± 8.69

-3.65

4.5

t = 0.23

p = 0.823

LDL

122.22 ± 15.7

124.93 ± 15.01

-4.3

9.77

t = 0.76

p = 0.449

eGFR

42.29 ± 6.6

48.4 ± 7.1

2.8

9.38

t = 3.69

p = 0.0001

CKD stage No. (%)

3 A

3B

8 (36.4%)

14 (63.6%)

67 (68.4%)

31 (31.6%)

0.53

3.7

X² = 7.8

p = 0.005

Relevant baseline medications

ACEI

11 (50%)

38 (38.77)

0.27

0.89

X² = 0.9

p = 0.45

ARBs

7 (31.8%)

34 (34.7%)

0.24

0.65

X² = 0.06

p = 0.83

SGLT2 inhibitors

6 (27.27%)

32 (32.6%)

0.22

0.67

X² = 0.17

p = 0.8

Febuxostat use

7 (31.8%)

53 (54.1%)

0.1

0.7

X² = 4.2

p = 0.048

Contrast volume, Mehran score and predicted CI-AKI-risk

Contrast volume, mean ± SD

184.09 ± 52.7

180.9 ± 41.27

-23.5

17.14

t= -0.31

p = 0.758

Mehran score, mean ± SD

8.13 ± 3.6

5.09 ± 2

-4.14

1.9

t= -8.2

p = 0.001

Predicted CI-AKI-risk (%) mean ± SD

16.4 ± 3.3

10.57 ± 3.23

-7.34

-4.3

t= -7.6

p = 0.001